Official research data conducted under real-world conditions in the UK shows that the COVID-19 vaccines from Pfizer / BioNTech and AstraZeneca / Oxford both show “high efficiency” in reducing infection. and reduces severe symptoms in the elderly.
The study was conducted based on data collected from January 2021 that showed that people over 80 years old received the first dose of either Vaccine This avoids an 80% risk of hospitalization within 3-4 weeks of injection. The study was published in the context of France and Germany considering changing views on the AstraZeneca / Oxford vaccine to be administered to people over 65 years of age.
UK Health Minister Matt Hancock welcomes the new study as “particularly good news”, emphasizing that both vaccines are highly effective in reducing the number of infections in people over 70 years of age.
According to Hancock, the detailed data of the study show that within 35 days after the first dose of injection, the AstraZeneca / Oxford vaccine will better protect the Pfizer / BioNTech vaccine. According to research, the vaccine’s Pfizer/ BioNTech has a protective effect of 57-61% after the first dose, while the AstraZeneca / Oxford vaccine is 60-73% effective.
Meanwhile, the head of the England regional health department, Mary Ramsay, rated the study as more convincing evidence that the vaccine was helping to reduce the number of infections and incidence of vong. emphasizes: “It is important to remember that protection is not complete and we do not yet know how much of this vaccines can reduce the risk of transmitting the virus from someone vaccinated to another.”